Table I.
Demographics and characteristics of evaluable and propensity score-matched patients.
| Evaluable patients | Propensity score-matched patients |
||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Variable | Statistics or category |
PET±CT (n = 447) |
CT alone (n = 537) |
p-value* | PET±CT (n = 361) |
CT alone (n = 361) |
p-value* |
| Age (years) | ≤ 60 | 247 (50%) | 250 (50%) | 0.0478 | 186 (50%) | 184 (50%) | 0.8973 |
| 61–70 | 108 (43%) | 146 (57%) | 92 (51%) | 90 (49%) | |||
| 71–80 | 70 (40%) | 105 (60%) | 63 (50%) | 62 (50%) | |||
| > 80 | 22 (38%) | 36 (62%) | 20 (44%) | 25 (56%) | |||
| Gender | Female | 241 (46%) | 286 (54%) | 0.8372 | 197 (51%) | 186 (49%) | 0.4121 |
| Male | 206 (45%) | 251 (55%) | 164 (48%) | 175 (52%) | |||
| Race | White | 404 (45%) | 485 (55%) | 0.7914 | 322 (50%) | 322 (50%) | 0.9048 |
| African American | 19 (50%) | 19 (50%) | 18 (55%) | 15 (45%) | |||
| Hispanic | 17 (40%) | 26 (60%) | 14 (45%) | 17 (55%) | |||
| Other | 7 (50%) | 7 (50%) | 7 (50%) | 7 (50%) | |||
| Histology by grade | Follicular grade 1 or 2 | 277 (41%) | 396 (59%) | < 0.0001 | 238 (50%) | 241 (50%) | 0.8911 |
| Follicular grade 3 | 122 (59%) | 85 (41%) | 81 (50%) | 80 (50%) | |||
| Missing | 48 | 56 | 42 | 40 | |||
| FLIPI risk group | Good (0–1) | 81 (42%) | 113 (58%) | 0.3111 | 66 (49%) | 68 (51%) | 0.8911 |
| Intermediate (2) | 138 (49%) | 145 (51%) | 110 (53%) | 96 (47%) | |||
| Poor (3–5) | 161 (45%) | 196 (55%) | 130 (49%) | 137 (51%) | |||
| Missing | 67 | 83 | 55 | 60 | |||
| Stage | Stage II | 69 (43%) | 92 (57%) | 0.4740 | 55 (51%) | 52 (49%) | 0.7533 |
| Stage III or IV | 378 (46%) | 445 (54%) | 306 (50%) | 309 (50%) | |||
| LDH | Normal | 258 (44%) | 329 (56%) | 0.0951 | 214 (51.0%) | 206 (49%) | 0.4906 |
| > ULN | 102 (51%) | 99 (49%) | 72 (48%) | 79 (52%) | |||
| Missing | 87 | 109 | 75 | 76 | |||
| Hemoglobin | < 12 g/dL | 110 (47%) | 125 (53%) | 0.6453 | 87 (48%) | 94 (52%) | 0.5152 |
| ≥ 12 g/dL | 321 (45%) | 391 (55%) | 260 (51%) | 251 (49%) | |||
| Missing | 16 | 21 | 14 | 16 | |||
| Nodal sites | < 5 | 224 (42%) | 305 (58%) | 0.0338 | 189 (50%) | 190 (50%) | 0.9399 |
| ≥ 5 | 213 (49%) | 220 (51%) | 165 (50%) | 164 (50%) | |||
| Missing | 16 | 21 | 7 | 7 | |||
| Extranodal sites | None | 169 (46%) | 195 (54%) | 0.2694 | 131 (49%) | 136 (51%) | 0.8645 |
| 1 | 114 (42%) | 201 (58%) | 130 (51%) | 123 (49%) | |||
| ≥ 2 | 123 (48%) | 134 (53%) | 95 (50%) | 96 (50%) | |||
| Missing | 11 | 7 | 5 | 6 | |||
| ECOG | 0: 100–90 | 214 (50%) | 216 (50%) | 0.2946 | 159 (50%) | 158 (50%) | 0.7092 |
| 1: 80–70 | 106 (46%) | 126 (54%) | 84 (47%) | 93 (53%) | |||
| ≥ 2: 60–10 | 15 (38%) | 24 (62%) | 14 (44%) | 18 (56%) | |||
| Missing | 112 | 171 | 104 | 92 | |||
| B symptoms | Yes | 145 (47%) | 166 (53%) | 0.6082 | 115 (49%) | 120 (51%) | 0.6913 |
| No | 302 (45%) | 371 (55%) | 246 (51%) | 241 (49%) | |||
| Bone marrow involvement | Yes | 166 (46%) | 197 (54%) | 0.3773 | 135 (51%) | 132 (49%) | 0.7451 |
| No | 201 (49%) | 210 (51%) | 156 (49%) | 161 (51%) | |||
| Missing | 80 | 130 | 70 | 68 | |||
| Geographic region | Midwest | 112 (36%) | 202 (64%) | < 0.0001 | 103 (50%) | 101 (50%) | 0.9924 |
| Northeast | 60 (49%) | 63 (51%) | 49 (50%) | 49 (50%) | |||
| Southeast | 166 (46%) | 193 (54%) | 141 (49%) | 145 (51%) | |||
| Southwest | 53 (67%) | 26 (33%) | 28 (53%) | 25 (47%) | |||
| West | 56 (51%) | 53 (49%) | 40 (49%) | 41 (51%) | |||
| Center type | Academic | 72 (39%) | 113 (61%) | 0.0485 | 68 (49%) | 70 (51%) | 0.8499 |
| Community | 375 (47%) | 424 (53%) | 293 (50%) | 291 (50%) | |||
| Induction treatment | R-monotherapy | 49 (31%) | 111 (69%) | < 0.0001 | 46 (49%) | 48 (51%) | 0.8249 |
| R-chemotherapy | 398 (48%) | 426 (52%) | 315 (50%) | 313 (50%) | |||
| R-CHOP | 232 (54%) | 201 (46%) | 0.0071 | 175 (51%) | 166 (49%) | 0.8713 | |
| R-CVP | 91 (45%) | 109 (55%) | 76 (49%) | 80 (51%) | |||
| R-Flu | 53 (41%) | 77 (59%) | 45 (47%) | 50 (53%) | |||
| R-Other | 22 (36%) | 39 (64%) | 19 (53%) | 17 (47%) | |||
| Duration of induction treatment | ≤ 84 days | 67 (34%) | 133 (67%) | 0.0006 | 58 (48%) | 63 (52%) | 0.6188 |
| 85–126 days | 226 (48%) | 248 (52%) | 181 (49%) | 188 (51%) | |||
| > 126 days | 154 (50%) | 156 (50%) | 122 (53%) | 110 (47%) | |||
a
Pearson chi-squared test.
CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase; PET, positron emission tomography; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine and prednisone; R-Flu, rituximab plus fludarabine; R-Other, rituximab plus other chemotherapy; ULN, upper limit of normal.